Royal Dutch Shell is not ruling out moving its headquarters from the Netherlands to Britain, the oil company’s chief executive Ben van Beurden said in a Dutch newspaper interview published on Saturday. Anglo-Dutch consumer products giant Unilever said last month it plans to ditch its dual Anglo-Dutch legal structure and create a single entity in Britain. Van Beurden did not explicitly say Shell wants to move its headquarters, het Financieele Dagblad said.

from Yahoo Finance https://ift.tt/2YVGzOG

Luke Lloyd, a wealth advisor at Strategic Wealth Partners, joins Yahoo Finance to highlight how some Americans are using the COVID-19 pandemic as an opportunity to reset retirement goals.

from Yahoo Finance https://ift.tt/2VJ4wGJ

Those following along with T-Mobile US, Inc. (NASDAQ:TMUS) will no doubt be intrigued by the recent purchase of shares…

from Yahoo Finance https://ift.tt/3dYny28

from Yahoo Finance https://ift.tt/31FuXRH

After a better-than-expected jobs report, stocks finished the holiday-shortened trading week on a strong note. Let's look at a few top stock trades for the first full week of July. Top Stock Trades for Tomorrow No. 1: Nio (NIO) Click to EnlargeSource: Chart courtesy of StockCharts.com The $5 to $6 zone was set to be a tough one for Nio (NYSE:NIO), which topped out in this area in the first quarter of 2020. Previously, this zone had been support for the stock, before Nio slumped badly in 2019.In any regard, electric car stocks have serious momentum right now — led by Tesla (NASDAQ:TSLA), which has amassed a market cap north of $200 billion.InvestorPlace – Stock Market News, Stock Advice & Trading TipsIn any regard, Nio shares keep pressing higher, up more than 30% so far this week. Investors undoubtedly have their eyes fixed on $10. * 7 American Manufacturing Stocks to Buy Before Recovery Let's see how the stock does with the $10 to $10.50 zone, which historically, has been resistance. If it continues as resistance, let's see that a pullback into the $6 to $7 area is met with support. Above $10.50 and the all-time highs up at $13.80 are in play. Top Stock Trades for Tomorrow No. 2: DocuSign (DOCU) Click to EnlargeSource: Chart courtesy of StockCharts.com Man, there's nothing else to say about DocuSign (NASDAQ:DOCU) other than the stock has been a complete beast.The stock never even tested its 200-day moving average during the March selloff. While shares dipped 29.9% from the February high to March low — outperforming the S&P 500 and Nasdaq during that time — the rebound has been stunning. Shares are now up more than 200% from that low.However, DocuSign stock nearly tagged $200 on Thursday and may be running out of momentum.I want to see $180 hold as support. If it doesn't, it puts uptrend support (blue line) and the 20-day moving average in play. On a larger dip, see if $150 and/or the 50-day moving average buoy the stock, whichever comes into play first. Top Stock Trades for Tomorrow No. 3: JPMorgan (JPM) Click to EnlargeSource: Chart courtesy of StockCharts.com Despite the rebound in the overall market, the bank stocks have struggled. For its part, JPMorgan (NYSE:JPM) is doing its best not to break down. But that's not exactly bullish.Shares are below all of the stock's key moving averages and are well off the June high near $115. In fact, just from that level, shares are down about 20%.On the plus side, JPM stock has carved out a nice bottom over the past few sessions. If it holds, the stock will create another higher low, giving bulls something to chew on. For them to maintain momentum though, shares need to reclaim the 50-day moving average, and preferably, the $100 to $102.50 area.If it falls below uptrend support, $82.50 is in play. Top Trades for Tomorrow No. 4: Moderna (MRNA) Click to EnlargeSource: Chart courtesy of StockCharts.com Moderna (NASDAQ:MRNA) has been a tricky stock lately, but it has traded very technically.While shares slipped about 6% in Thursday's session and lost the 50-day moving average, support near $55 is holding up. If it continues to hold, see that MRNA stock reclaims the 50-day and 20-day moving averages.Above those levels puts recent range resistance in play, up near $67.50. Pushing above that could put a move up toward $80 on the table.If $55 support breaks, shares could see $45.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post 4 Top Stock Trades for Monday: NIO, DOCU, JPM, MRNA appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/2BBRfsS

Jul.02 — David Bloom, global head of foreign exchange strategy at HSBC, discusses the dollar’s status as the world’s reserve currency, why the euro isn’t going up or down, and why he’s still bearish on the pound. He speaks on “Bloomberg Markets: European Open.”

from Yahoo Finance https://ift.tt/38pQS0s

Nio (NYSE:NIO) has shifted into turbo drive Thursday, but some investors might question whether shares have gas left in the tank. Let's take a look at what's happening with Nio stock to determine a risk-adjusted solution to better navigate its thrilling ride up today.Source: Sundry Photography / Shutterstock.com The market is offering investors some pre-July 4 fireworks to finish off the abbreviated workweek. The SPDR S&P Mid-Cap 400 ETF (NYSEARCA:MDY) is up 2.25% on much stronger-than-forecast monthly jobs data. The index, however, is still struggling inside a trading range more than a month in-the-making after a historic bull-run from March's corrective bottom.But that's not stopping recently crowned mid-cap Nio, whose shares continue to trade aggressively higher.InvestorPlace – Stock Market News, Stock Advice & Trading TipsNIO stock is up nearly 17% Thursday and leading its market-weighted peers to fresh relative highs. And those gains come on top of a near 100% return over the past month, which took shares from a small-cap valuation of around $3.5 billion to today's firm $8 billion mid-cap membership.So, what gives? Why is Nio continuing to race higher? Overnight, the EV outfit updated investors with its much better-than-forecast June and second quarter deliveries results. Backing today's joyride are record-breaking sales of more than 10,000 vehicles for the quarter amid the novel coronavirus. That's not all either. * 7 Utilities Stocks to Buy With Reassuring Dividends The solid performance represents boastful year-over-year growth of 190% and compares favorably to the first quarter's gain of around 170%. At the same time, Nio's cumulative deliveries on its ES8 and ES6 models reached more than 46,000 and exceeded the high end of the companies prior forecast. And the good news doesn't stop there.Nio investors may also want to thank EV peer Tesla (NASDAQ:TSLA). The outfit also offered a much stronger-than-expected deliveries update to its investors. And similarly, shares are bolting upwards of 8.50% to all-time-highs.A competitor's own good fortunes could spell doom-and-gloom under certain scenarios. But with Wall Street more or less fixated on "the good" from any and all reports and key data as economies look to put Covid-19 in the rear-view mirror, in today's market Tesla is a backseat driver for NIO stock in a good sort of way. Nio Stock Weekly Chart Source: Charts by TradingViewLooking at the price chart, shares of NIO are currently at risk of faltering in the short-term. The observation is supported by price action now in its fourth straight week outside of the weekly Bollinger Band. Stochastics have also formed a bearish crossover in overbought territory. But with Nio's recent and much-needed cash injection, still smallish capitalization and the known ability for momentum to take growth stocks like Nio strongly higher, the interpretation is not to rashly discount Nio's continued upside potential.Taking a second look at the price chart, Nio has also formed a very constructive saucer or cup-shaped corrective base over its time as publicly traded company. It's bullish. Now, with shares testing the 62% retracement level, NIO stock is inside the upper half of the pattern and well-positioned for future gains. And potentially, Nio investors should be rewarded with a breakout to all-time-highs in the coming months.Given that in the near-term Nio may be due for a rest, but there are no guarantees momentum won't continue to build. Being much more optimistic longer-term, my recommendation is investors consider the options market for assistance with a stronger risk-adjusted way to position in Nio. One favored strategy with shares near $9 is the Weeklys 15' Jan $10 / $17 bull call spread for $1.35 or better.The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post How to Approach Nio Stock At New All-Time Highs appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/2NRd0HL

Editor's note: This article is part of InvestorPlace.com's Best Stocks for 2020 contest. Matt McCall's pick for the contest is Aimmune Therapeutics (NASDAQ:AIMT).Six months ago, I introduced you to Aimmune Therapeutics (NASDAQ:AIMT) as my pick in the Best Stocks for 2020 contest. It's a leading biopharmaceutical that focuses specifically on the unmet needs of people who suffer from food allergies.The recommendation was in anticipation of the approval of its lead drug candidate. That worked out just as expected. Aimmune's treatment for peanut allergies got the green light from the U.S. Food and Drug Administration in January.InvestorPlace – Stock Market News, Stock Advice & Trading TipsThat was — and still is — a very big deal. Palforzia is the first-ever treatment for peanut allergies, and its approval sent the stock to a fresh one-year high.And then the novel coronavirus hit…The first patients were given Palforzia after the January approval, but for all intents and purposes, the rollout of this one-of-a-kind treatment came to a screeching halt. As federal and local governments implemented stay-at-home orders, allergy sufferers were forced to forgo treatments. The Coronavirus Derails AIMT StockThe healthcare system's full attention was on preparing for what some experts feared would be a flood of patients hitting hospitals. All elective surgeries and treatments came to a halt to focus on Covid-19.It did not make sense to have generally healthy allergy patients come to a doctor's office and potentially contract or unknowingly spread the virus. Peanut allergy patients have dealt with the issue for their entire lives, so apart from true emergency situations, it was not considered a critical treatment during a pandemic. * 7 Utilities Stocks to Buy With Reassuring Dividends Still, Palforzia is a much-needed breakthrough. As widespread as food allergies are, they've gotten very little attention from pharmaceutical companies. It's surprising to me that the first FDA-approved preventative treatment for peanut allergies just occurred five months ago, but it puts Palforzia in a great spot.According to Reportbuyer, Aimmune could have 67% of the peanut allergy market by 2027 — equal to $3 billion. That's a huge number for a company that has yet to generate any revenue and has a current market value of $1.1 billion.The drug is also a little more complicated than some others. Each patient receives small amounts of peanut protein through several visits to the allergist's office. They need to be closely monitored to assure there are no adverse side effects.Under normal circumstances, a few trips to the allergist to cure a potentially deadly reaction would be a godsend. However, when in the midst of a global pandemic that has killed more than 500,000 people, even something as serious as a peanut allergy may not sound so bad. In addition, when allergy sufferers stay home, they can distance themselves from potential triggers. A Return to Normal Will Boost Aimmune HigherBut countries and states are starting to reopen and life will soon return to something resembling normal. As it does, and kids go back to school while adults go back to offices and traveling, the risk of a potentially deadly peanut allergy becomes top of mind again.As of today and likely for the foreseeable future, Aimmune will have the only treatment available for peanut allergies.That's huge. And it gives Palforzia the potential to be a billion-dollar blockbuster. According to Evaluate Pharma, the drug could bring in $1.28 billion in annual sales by 2024. For a company that generated basically no sales last year, that would be a monumental achievement.Aimmune officially announced Palforzia's delay in May. At the same time, the company also said that its supply chain has not been affected and that once the stay-at-home orders are lifted, it will be ready to supply the allergists with products. The supply chain for ongoing trials is also unaffected as the company continues to push forward with testing new treatments. Keeping Our Eye on the Big PictureDue to the delay in Palforzia's rollout, revenue expectations for this year have dropped 36% from $30 million to $19 million. Next year, the treatment should be able to expand, with revenue projected to jump 4x to $130 million. That number continues to more than double annually until reaching the $1 billion milestone in 2024.By that time, earnings should be close to $6 per share — a world away from the loss of $3.97 in 2019. Some estimates are as high as $10.92 for 2024.With those numbers in mind, let's put a valuation on Aimmune. Considering the robust growth of both revenue and earnings, which is all but inevitable, it is justified to assume the stock could trade at 5x sales and 30x earnings.At five times sales of $1.28 billion, Aimmune would have a value of $6.4 billion, or $97 per share. That's a 470% gain from current prices.And if Aimmune were to trade at 30x earnings of $6 per share, it would reach $180 — or 960% above where it trades right now.Splitting the difference gets us to $138.50, a gain of 715% from the current price around $17.Of course, all of this is assuming that life gets back to normal. If I am wrong and life does not return to normal, there are far greater concerns than peanut allergies. I put the odds of this at basically zero. The reason I am so confident is that the U.S. and the world have recovered from even worse situations for thousands of years.We can defeat the Covid-19 pandemic, just like all other crises that came before it. Best Stocks: Buy AIMT Stock Right NowAimmune has received several analyst downgrades since the start of the pandemic because of Palforzia's delay. Analysts are taking a very short-term view on the stock, even though they remain bullish long term.And this gives investors a great buying opportunity.The unfortunate fact is that peanut allergies are not going anywhere. They will still exist once the pandemic passes. And as restrictions loosen up, demand for Palforzia will boom. Other investors are looking ahead to this yet, which makes Aimmune an incredibly compelling opportunity at current prices.With a market cap of $1.1 billion and projected sales of the drug expected to be in that same ballpark, this stock is flat-out cheap.Matthew McCall left Wall Street to actually help investors — by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Best Stocks for 2020: Expect Aimmune Stock to Come Back in Full Force appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/31PDwsW

On Thursday, Wedbush analyst Dan Ives raised his bull case price target for shares of Tesla to $2,000 from $1,500. While his base case was lifted from $1,000 to $1,250 (a street high), he maintains a neutral rating on the stock. The Final Round panel discusses the bullish call, and the road ahead for the electric automaker.

from Yahoo Finance https://ift.tt/38nEM81